(secondQuint)GV 1001 Immunotherapy in Patients With Non-small Cell Lung Cancer (NSCLC).

 Survival in patients with locally advanced, inoperable NSCLC may be improved if local control can be achieved with concurrent chemo radiotherapy .

After completed standard chemo-and radiation therapy; the safety and efficacy of vaccination therapy will be measured as time to progression after treatment with GV1001.

 Analysis of changes in T-cell subpopulations and cytokines in peripheral blood will be performed.

.

 GV 1001 Immunotherapy in Patients With Non-small Cell Lung Cancer (NSCLC)@highlight

To examine the safety and efficacy of telomerase peptide vaccination ( stimulation of the immune system) in patients with NSCLC after having been treated with conventional therapy with radiotherapy and docetaxel as a radiosensitizer.

